Theoretical and experimental studies on the interaction of biphenyl ligands with human and murine PD-L1: Up-to-date clues for drug design

[1]  M. Yin,et al.  Novel Small-Molecule PD-L1 Inhibitor Induces PD-L1 Internalization and Optimizes the Immune Microenvironment. , 2022, Journal of medicinal chemistry.

[2]  M. Morar,et al.  Effects of small molecule-induced dimerization on the programmed death ligand 1 protein life cycle , 2022, Scientific reports.

[3]  A. Mai,et al.  PD-L1 small-molecule modulators: a new hope in epigenetic-based multidrug cancer therapy? , 2022, Drug discovery today.

[4]  R. Offringa,et al.  The expanding role for small molecules in immuno-oncology , 2022, Nature Reviews Drug Discovery.

[5]  R. Satchi‐Fainaro,et al.  Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment , 2022, Journal for ImmunoTherapy of Cancer.

[6]  A. Ganesan,et al.  Leveraging structural and 2D-QSAR to investigate the role of functional group substitutions, conserved surface residues and desolvation in triggering the small molecule-induced dimerization of hPD-L1 , 2022, BMC Chemistry.

[7]  C. Luchinat,et al.  Epitope Mapping and Binding Assessment by Solid-State NMR Provide a Way for the Development of Biologics under the Quality by Design Paradigm , 2022, Journal of the American Chemical Society.

[8]  Gefei Wang,et al.  Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents , 2022, Acta pharmaceutica Sinica. B.

[9]  Huiyong Sun,et al.  Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation. , 2022, Journal of medicinal chemistry.

[10]  Dandan Yuan,et al.  Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy. , 2021, Future medicinal chemistry.

[11]  Jieqing Liu,et al.  Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction. , 2021, European journal of medicinal chemistry.

[12]  T. Holak,et al.  PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action , 2021, International journal of molecular sciences.

[13]  E. Novellino,et al.  Interfering with the Tumor-Immune Interface: Making Way for Triazine-Based Small Molecules as Novel PD-L1 Inhibitors. , 2021, Journal of medicinal chemistry.

[14]  Kuojun Zhang,et al.  Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. , 2021, Journal of medicinal chemistry.

[15]  Yulong Jin,et al.  Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization , 2021, International journal of molecular sciences.

[16]  B. Musielak,et al.  Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists , 2021, ACS medicinal chemistry letters.

[17]  Bhavna S. Paratala,et al.  Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1 , 2021, Nature Communications.

[18]  T. Holak,et al.  Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction , 2021, Journal of medicinal chemistry.

[19]  L. Skalniak,et al.  Human and mouse PD-L1: similar molecular structure, but different druggability profiles , 2020, iScience.

[20]  Yingfeng Tu,et al.  Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment. , 2020, Journal of medicinal chemistry.

[21]  T. Holak,et al.  Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint , 2020, Journal of medicinal chemistry.

[22]  C. Bailly,et al.  Flurbiprofen as a biphenyl scaffold for the design of small molecules binding to PD-L1 protein dimer. , 2020, Biochemical pharmacology.

[23]  Zhengping Hu,et al.  PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice , 2020, PloS one.

[24]  Lianhong Li,et al.  PD-1/PD-L1 pathway: current researches in cancer. , 2020, American journal of cancer research.

[25]  H. Wasan,et al.  Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis , 2020, Scientific Reports.

[26]  C. Bailly,et al.  Protein homodimer sequestration with small molecules: focus on PD-L1. , 2020, Biochemical pharmacology.

[27]  K. No,et al.  Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method , 2019, Scientific Reports.

[28]  Lai Xu,et al.  Comprehensive in vitro characterization of PD-L1 small molecule inhibitors , 2019, Scientific Reports.

[29]  T. Holak,et al.  Design, synthesis, evaluation and structural studies of C2-symmetric small molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) protein-protein interaction. , 2019, Journal of medicinal chemistry.

[30]  Katarzyna Guzik,et al.  Development of the Inhibitors That Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles , 2019, Molecules.

[31]  D. Trafalis,et al.  Targeting Programmed Cell Death ‐1 (PD‐1) and Ligand (PD‐L1): A new era in cancer active immunotherapy , 2019, Pharmacology & therapeutics.

[32]  S. Sidhu,et al.  Humanized Mice for the Study of Immuno-Oncology. , 2018, Trends in immunology.

[33]  E. Novellino,et al.  HMGB1 binds to the KRAS promoter G-quadruplex: a new player in oncogene transcriptional regulation? , 2018, Chemical communications.

[34]  Hakho Lee,et al.  Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles , 2018, Science Advances.

[35]  X. Thuru,et al.  PD-1/PD-L1 binding studies using microscale thermophoresis , 2017, Scientific Reports.

[36]  L. Skalniak,et al.  Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells , 2017, Oncotarget.

[37]  T. Holak,et al.  Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. , 2017, Journal of medicinal chemistry.

[38]  Laurence Zitvogel,et al.  Mouse models in oncoimmunology , 2016, Nature Reviews Cancer.

[39]  Chenzhong Liao,et al.  From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. , 2016, Drug discovery today.

[40]  K. Zak,et al.  Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1) , 2016, Oncotarget.

[41]  Berk Hess,et al.  GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .

[42]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[43]  Lon Smith,et al.  Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.

[44]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[45]  帕塔伊尔·戈文丹·奈尔·萨西库玛,et al.  1,2,4-oxadiazole derivatives as immunomodulators , 2014 .

[46]  Луис С. Чупак,et al.  Compounds useful as immunomodulators , 2014 .

[47]  Xiumin Wang,et al.  PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients , 2014, Cancer Immunology, Immunotherapy.

[48]  John E. Ladbury,et al.  Structure and Interactions of the Human Programmed Cell Death 1 Receptor* , 2013, The Journal of Biological Chemistry.

[49]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[50]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[51]  Dieter Braun,et al.  Molecular interaction studies using microscale thermophoresis. , 2011, Assay and drug development technologies.

[52]  Jan H. Jensen,et al.  PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. , 2011, Journal of chemical theory and computation.

[53]  David Calkins,et al.  Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution , 2010, J. Comput. Aided Mol. Des..

[54]  Thomas E. Cheatham,et al.  Molecular Dynamics Simulations of the Dynamic and Energetic Properties of Alkali and Halide Ions Using Water-Model-Specific Ion Parameters , 2009, The journal of physical chemistry. B.

[55]  T. Cheatham,et al.  Determination of Alkali and Halide Monovalent Ion Parameters for Use in Explicitly Solvated Biomolecular Simulations , 2008, The journal of physical chemistry. B.

[56]  G. Zhu,et al.  B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. , 2008, Blood.

[57]  Jeremy R. Greenwood,et al.  Epik: a software program for pKa prediction and protonation state generation for drug-like molecules , 2007, J. Comput. Aided Mol. Des..

[58]  M. Parrinello,et al.  Canonical sampling through velocity rescaling. , 2007, The Journal of chemical physics.

[59]  L. Zitvogel,et al.  Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.

[60]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[61]  Richard A. Friesner,et al.  Integrated Modeling Program, Applied Chemical Theory (IMPACT) , 2005, J. Comput. Chem..

[62]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[63]  B. Honig,et al.  A hierarchical approach to all‐atom protein loop prediction , 2004, Proteins.

[64]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[65]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[66]  Z. Xiang,et al.  On the role of the crystal environment in determining protein side-chain conformations. , 2002, Journal of molecular biology.

[67]  Berk Hess,et al.  LINCS: A linear constraint solver for molecular simulations , 1997, J. Comput. Chem..

[68]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[69]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[70]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[71]  A. Becke.  Density-functional thermochemistry. III. The role of exact exchange , 1993 .

[72]  H. Berendsen,et al.  A LEAP-FROG ALGORITHM FOR STOCHASTIC DYNAMICS , 1988 .

[73]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[74]  P. Kollman,et al.  An approach to computing electrostatic charges for molecules , 1984 .

[75]  S. Nosé,et al.  Constant pressure molecular dynamics for molecular systems , 1983 .

[76]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[77]  M. Parrinello,et al.  Polymorphic transitions in single crystals: A new molecular dynamics method , 1981 .

[78]  Clemens C. J. Roothaan,et al.  New Developments in Molecular Orbital Theory , 1951 .

[79]  S. Romagnani.  Immunological tolerance and autoimmunity , 2006, Internal and emergency medicine.

[80]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[81]  A. Abbas,et al.  The enemy within: keeping self-reactive T cells at bay in the periphery , 2002, Nature Reviews Immunology.